Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma

被引:24
|
作者
Li, Hanyu [1 ]
Long, Junyu [1 ]
Xie, Fucun [1 ]
Kang, Kai [1 ]
Shi, Yue [1 ]
Xu, Weiyu [1 ]
Wu, Xiaoqian [1 ]
Lin, Jianzhen [1 ]
Xu, Haifeng [1 ]
Du, Shunda [1 ]
Xu, Yiyao [1 ]
Zhao, Haitao [1 ]
Zheng, Yongchang [1 ]
Gu, Jin [2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, 1 Shuaifu Rd, Beijing 100730, Peoples R China
[2] Tsinghua Univ, MOE Key Lab Bioinformat, BNIRST Bioinformat Div, Dept Automat, 30 Shuangqing Rd, Beijing 100084, Peoples R China
基金
北京市自然科学基金;
关键词
transcriptomic analysis; hub genes; differentially expressed protein-coding genes; cholangiocarcinoma; prognosis; biomarker; THERAPEUTIC TARGETS; EXPRESSION; PROTEIN; CHEMOTHERAPY; SUBTYPES; CANCER; HER-2; INDEX; CDK1;
D O I
10.3892/or.2019.7318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cholangiocarcinoma (CCA) is acknowledged as the second most commonly diagnosed primary liver tumor and is associated with a poor patient prognosis. The present study aimed to explore the biological functions, signaling pathways and potential prognostic biomarkers involved in CCA through transcriptomic analysis. Based on the transcriptomic dataset of CCA from The Cancer Genome Atlas (TCGA), differentially expressed protein-coding genes (DEGs) were identified. Biological function enrichment analysis, including Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, was applied. Through protein-protein interaction (PPI) network analysis, hub genes were identified and further verified using open-access datasets and qRT-PCR. Finally, a survival analysis was conducted. A total of 1,463 DEGs were distinguished, including 267 upregulated genes and 1,196 downregulated genes. For the GO analysis, the upregulated DEGs were enriched in 'cadherin binding in cell-cell adhesion', 'extracellular matrix (ECM) organization' and 'cell-cell adherens junctions'. Correspondingly, the downregulated DEGs were enriched in the 'oxidation-reduction process', 'extracellular exosomes' and 'blood microparticles'. In regards to the KEGG pathway analysis, the upregulated DEGs were enriched in 'ECM-receptor interactions', 'focal adhesions' and 'small cell lung cancer'. The downregulated DEGs were enriched in 'metabolic pathways', 'complement and coagulation cascades' and 'biosynthesis of antibiotics'. The PPI network suggested that CDK1 and another 20 genes were hub genes. Furthermore, survival analysis suggested that CDK1, MKI67, TOP2A and PRC1 were significantly associated with patient prognosis. These results enhance the current understanding of CCA development and provide new insight into distinguishing candidate biomarkers for predicting the prognosis of CCA.
引用
收藏
页码:1833 / 1842
页数:10
相关论文
共 50 条
  • [1] Identification of potential biomarkers and survival analysis for oral squamous cell carcinoma: A transcriptomic study
    de Paula Souza, Daniela Paola Santos
    Pereira Queiroz, Lorena dos Reis
    de Souza, Marcela Goncalves
    de Jesus, Sabrina Ferreira
    Batista Gomes, Emisael Stenio
    Vitorino, Rogerio Trancoso
    Sousa Santos, Sergio Henrique
    Farias, Lucyana Conceicao
    Batista de Paula, Alfredo Mauricio
    Silveira Vasconcelos D'Angelo, Marcos Flavio
    de Carvalho Fraga, Carlos Alberto
    Sena Guimaraes, Andre Luiz
    ORAL DISEASES, 2023, 29 (07) : 2658 - 2666
  • [2] Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art
    Lang, Sven A.
    Bednarsch, Jan
    Joechle, Katharina
    Amygdalos, Iakovos
    Czigany, Zoltan
    Heij, Lara
    Ulmer, Tom F.
    Neumann, Ulf P.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (05) : 497 - 510
  • [3] Screening and Validation of Immune Infiltration-Related Prognostic Biomarkers for Cholangiocarcinoma
    Liu, Yu
    Tang, Yipeng
    Ma, Chi
    Yu, Jingbo
    Qu, Liancong
    Zhang, Yue
    Liu, Hangyu
    Gai, Xuefeng
    Jia, Youpeng
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (01) : 149 - 159
  • [4] Proteomics Analysis and Evaluation of Biomarkers for Detection of Cholangiocarcinoma
    Sriwanitchrak, Pramote
    Viyanant, Vithoon
    Chaijaroenkul, Wanna
    Srivatanakul, Petcharin
    Gram, Hans Rudi
    Eursiddhichai, Veerachai
    Na-Bangchang, Kesara
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (06) : 1503 - 1510
  • [5] Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile
    Wang, Bin
    Chen, Liang
    Chang, Hao-Teng
    BIOMARKERS IN MEDICINE, 2016, 10 (06) : 613 - 619
  • [6] Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma
    Tang, Zengwei
    Yang, Yuan
    Zhang, Jinduo
    Fu, Wenkang
    Lin, Yanyan
    Su, Gang
    Li, Yan
    Meng, Wenbo
    Li, Xun
    Xie, Xiaodong
    JOURNAL OF CANCER, 2019, 10 (17): : 3985 - 3999
  • [7] Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma
    Pawaskar, Rishaan
    Huang, Kevin Zhang
    Pham, Helen
    Nagrial, Adnan
    Wong, Mark
    O'Neill, Siobhan
    Pleass, Henry
    Yuen, Lawrence
    Lam, Vincent W. T.
    Richardson, Arthur
    Pang, Tony
    Nahm, Christopher B.
    CANCERS, 2024, 16 (04)
  • [8] Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma
    Da, Zijian
    Gao, Long
    Su, Gang
    Yao, Jia
    Fu, Wenkang
    Zhang, Jinduo
    Zhang, Xu
    Pei, Zhaoji
    Yue, Ping
    Bai, Bing
    Lin, Yanyan
    Meng, Wenbo
    Li, Xun
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [9] Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis
    Sun, Chao
    Zhu, Jie
    Wu, Bin
    Chen, Jianlei
    Zhu, Zhenwei
    Cai, Peng
    Guo, Wanliang
    Gu, Zhicheng
    Wang, Jian
    Huang, Shungen
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2125 - 2139
  • [10] Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA
    Xu, Lei
    Xiao, Ting
    Xu, Ling
    Yao, Wei
    FRONTIERS IN ONCOLOGY, 2022, 12